前列腺特异性膜抗原正电子发射断层扫描（PET）对强化或弱化晚期肾细胞癌管理的临床影响。
Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management.
机构信息
Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, 4029, Australia.
出版信息
Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):295-303. doi: 10.1007/s00259-023-06380-4. Epub 2023 Aug 18.
PURPOSE
There is an emerging role of the use of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in renal cell carcinoma. Herein, we report our experience in use of PSMA PET in recurrent or metastatic renal cell carcinoma (RCC).
METHODS
A retrospective analysis of all patients who underwent PSMA PET for suspected recurrent or de-novo metastatic RCC between 2015 and 2020 at three institutions was performed. The primary outcome was change in management (intensification or de-intensification) following PSMA PET scan. Secondary outcomes included histopathological correlation of PSMA avid sites, comparison of sites of disease on PSMA PET to diagnostic CT and time to systemic treatment.
目的
使用前列腺特异性膜抗原（PSMA）正电子发射断层扫描（PET）在肾细胞癌中的作用正在不断显现。本文报告了我们在复发性或转移性肾细胞癌（RCC）中使用 PSMA PET 的经验。
方法
对 2015 年至 2020 年间在三个机构接受 PSMA PET 检查以怀疑复发性或新发转移性 RCC 的所有患者进行回顾性分析。主要结果是 PSMA PET 扫描后管理方式的变化（强化或非强化）。次要结果包括 PSMA 摄取部位的组织病理学相关性、PSMA PET 与诊断 CT 上疾病部位的比较以及全身治疗的时间。
Zotero 插件